Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.

Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.

ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.

The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.

Molecular glues are redefining how we approach drug discovery, enabling the targeting of proteins once considered “undruggable.” Unlike traditional small molecules that bind directly to a single protein, molecular glues act as mediators, stabilizing interactions between two proteins to drive a specific biological outcome. This breakthrough mechanism is particularly valuable for targeted protein degradation (TPD) and other therapeutic…